Key result
Evacetrapib fails to improve cardiovascular outcomes, mirroring earlier CETP inhibitor torcetrapib setbacks.
Why the study?
The first CETP inhibitor, torcetrapib, was discontinued due to increased cardiovascular events from off-target effects, motivating investigation into evacetrapib's efficacy.
Discusses the reasons for the lack of cardiovascular efficacy of evacetrapib and the adverse effects of earlier CETP inhibitors like torcetrapib.
Requires clinical caution with CETP inhibitors; leaves open cardiovascular outcomes pending randomized trials.
Cholesteryl ester transfer protein (CETP) inhibitors are a drug class targeting the enzyme CETP (1). The first CETP inhibitor, torcetrapib, was discontinued because of increased cardiovascular events that were attributed to off-target adverse effects (increased aldosterone and blood pressure) (2).
No takes yet. Share an insight, caveat, or question.
Filippatos et al. (2017) studied this question. Evacetrapib lacked efficacy for cardiovascular outcomes, while the first CETP inhibitor torcetrapib was discontinued due to increased cardiovascular events from off-target effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: